檢索結果 - Ingrid M.E. Desar

Refine Results
  1. 1
    Systemic Treatment for Adults with Synovial Sarcoma

    Systemic Treatment for Adults with Synovial Sarcoma 由 Ingrid M.E. Desar, Emmy D.G. Fleuren, Winette T.A. van der Graaf

    出版 2018
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  2. 2
    Systemic treatment in adult uterine sarcomas

    Systemic treatment in adult uterine sarcomas 由 Ingrid M.E. Desar, P.B. Ottevanger, Charlotte Benson, Winette T.A. van der Graaf

    出版 2017
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Primary sarcoma of the heart: case report and literature review

    Primary sarcoma of the heart: case report and literature review 由 Rieneke G. Moeri-Schimmel, Elisabeth Pras, Ingrid M.E. Desar, Stijn Krol, Pètra M. Braam

    出版 2020
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  4. 4
    The sarcoma diagnostic interval: a systematic review on length, contributing factors and patient outcomes

    The sarcoma diagnostic interval: a systematic review on length, contributing factors and patient outcomes 由 Vicky L. M. N. Soomers, Olga Husson, Robin Young, Ingrid M.E. Desar, Winette van der Graaf

    出版 2020
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  5. 5
    Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose

    Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose 由 Kim Westerdijk, Ingrid M.E. Desar, Neeltje Steeghs, Winette T.A. van der Graaf, Nielka P. van Erp

    出版 2019
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  6. 6
    Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma

    Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma 由 Annemiek van Maldegem, Anthony P. Conley, Piotr Rutkowski, Shreyaskumar Patel, Iwona Ługowska, Ingrid M.E. Desar, Judith V.M.G. Bovée, Hans Gelderblom

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Factors influencing the quality and functioning of oncological multidisciplinary team meetings: results of a systematic review

    Factors influencing the quality and functioning of oncological multidisciplinary team meetings: results of a systematic review 由 Janneke E. W. Walraven, Olga L. van der Hel, Jacobus J. M. van der Hoeven, V.E.P.P. Lemmens, Rob H.A. Verhoeven, Ingrid M.E. Desar

    出版 2022
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  8. 8
    Dose recommendations for anticancer drugs in patients with renal or hepatic impairment

    Dose recommendations for anticancer drugs in patients with renal or hepatic impairment 由 Stefanie D. Krens, Gerben Lassche, Frank G. A. Jansman, Ingrid M.E. Desar, Nienke A. G. Lankheet, David M. Burger, Carla M.L. van Herpen, Nielka P. van Erp

    出版 2019
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  9. 9
    Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib

    Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib 由 Nienke A. G. Lankheet, Ingrid M.E. Desar, Sasja F. Mulder, David M. Burger, Dina M. Kweekel, Carla M.L. van Herpen, Winette T.A. van der Graaf, Nielka P. van Erp

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Overall Survival of Patients with Myxofibrosarcomas: An Epidemiological Study

    Overall Survival of Patients with Myxofibrosarcomas: An Epidemiological Study 由 Chiel A. J. van der Horst, Sabien L. M. Bongers, Yvonne M.H. Versleijen‐Jonkers, Vincent K.Y. Ho, Pètra M. Braam, Uta Flucke, Johannes H.W. de Wilt, Ingrid M.E. Desar

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study

    Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study 由 Sasja F. Mulder, Dirk Bertens, Ingrid M.E. Desar, Kris CP Vissers, Peter F.A. Mulders, Cornelis J.A. Punt, Dick-Johan van Spronsen, Johan F. Langenhuijsen, Roy P. C. Kessels, Carla M.L. van Herpen

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study

    Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study 由 Anastasia Constantinidou, Nicolas Sauvé, Silvia Stacchiotti, Jean‐Yves Blay, Bruno Vincenzi, Giovanni Grignani, Piotr Rutkowski, Michele Guida, Nadia Hindi, Alexander Klein, Thibaud Valentin, Jozef Šufliarský, Ingrid M.E. Desar, Neeltje Steeghs, Saskia Litière, Hans Gelderblom, Robin L. Jones

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Impact of Mutation Profile on Outcomes of Neoadjuvant Therapy in GIST

    Impact of Mutation Profile on Outcomes of Neoadjuvant Therapy in GIST 由 Mahmoud Mohammadi, Evelyne Roets, Roos F. Bleckman, Astrid W. Oosten, Dirk J. Grünhagen, Ingrid M.E. Desar, Han J. Bonenkamp, Anna K.L. Reyners, Boudewijn van Etten, Henk H. Hartgrink, Marta Fiocco, Yvonne Schrage, Neeltje Steeghs, Hans Gelderblom

    出版 2025
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas

    DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas 由 Marije E. Weidema, Ellen van de Geer, Christian Koelsche, Ingrid M.E. Desar, Patrick Kemmeren, Melissa H.S. Hillebrandt-Roeffen, Vincent K.Y. Ho, Winette T.A. van der Graaf, Yvonne M.H. Versleijen‐Jonkers, Andreas von Deimling, Uta Flucke

    出版 2019
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients

    Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients 由 Ingrid M.E. Desar, Joannes F.M. Jacobs, Christina A. Hulsbergen‐vandeKaa, Wim J.G. Oyen, Peter F.A. Mulders, Winette T.A. van der Graaf, Gosse J. Adema, Carla M.L. van Herpen, I. Jolanda M. de Vries

    出版 2010
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)

    Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Orga... 由 Lars H. Lindner, Saskia Litière, Stefan Sleijfer, Charlotte Benson, Antoîne Italiano, Bernd Kasper, Christina Messiou, Hans Gelderblom, Eva Wardelmann, Axel Le Cesne, Jean‐Yves Blay, Sandrine Marréaud, Nadia Hindi, Ingrid M.E. Desar, Alessandro Gronchi, Winette T.A. van der Graaf

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group–Therapeutic Drug Monitoring Protocol for a Prospective Study

    Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group–Therapeutic Drug Monitoring Protocol for a Prospective Study 由 Stefanie L. Groenland, Ruben A.G. van Eerden, Remy B. Verheijen, Stijn L.W. Koolen, Dirk Jan A. R. Moes, Ingrid M.E. Desar, Anna K.L. Reyners, Hans Gelderblom, Nielka P. van Erp, Ron H.J. Mathijssen, Alwin D. R. Huitema, Neeltje Steeghs

    出版 2019
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  18. 18
    The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

    The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanc... 由 Udai Banerji, D. Ross Camidge, Henk M.W. Verheul, Roshan Agarwal, Debashis Sarker, Stan B. Kaye, Ingrid M.E. Desar, Johanna N.H. Timmer-Bonte, Sabine Eckhardt, Karl D. Lewis, Kathryn H. Brown, Mireille Cantarini, Clive Morris, Sarah M.A. George, Paul D. Smith, Carla M.L. van Herpen

    出版 2010
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent

    Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent 由 Anke van Erp, Yvonne M.H. Versleijen‐Jonkers, Melissa H.S. Hillebrandt-Roeffen, Laurens van Houdt, Mark A.J. Gorris, Laura S. van Dam, Thomas Mentzel, Marije E. Weidema, C. Dilara Savci‐Heijink, Ingrid M.E. Desar, Johannes H. M. Merks, Max M. van Noesel, Janet Shipley, Winette T.A. van der Graaf, Uta Flucke, Friederike Meyer‐Wentrup

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study

    Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study 由 Stefanie L. Groenland, Ruben A.G. van Eerden, Kim Westerdijk, Marinda Meertens, Stijn L.W. Koolen, Dirk Jan A. R. Moes, Nanné K. de Vries, Hilde Rosing, H-M.M.B. Otten, Annelie Vulink, Ingrid M.E. Desar, Alex L.T. Imholz, Hans Gelderblom, Nielka P. van Erp, Jos H. Beijnen, Ron H.J. Mathijssen, Alwin D. R. Huitema, Neeltje Steeghs

    出版 2022
    獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: